Instem plc: Final Results - Revision history

Manos at 13:58, 3 September 2022

2022-09-03T13:58:41Z

← Older revision		Revision as of 14:58, 3 September 2022
Line 1:		Line 1:
			{{Cover Image\|[[File:Instem plc update cover image 7.jpg]]}}

	== Summary ==		== Summary ==
	Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces its unaudited results for the year ended 31 December 2021 (the "Period").		Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces its unaudited results for the year ended 31 December 2021 (the "Period").

95.149.241.133 at 09:34, 3 September 2022

2022-09-03T09:34:53Z

Show changes

95.149.241.133 at 08:07, 3 September 2022

2022-09-03T08:07:41Z

← Older revision		Revision as of 09:07, 3 September 2022
Line 1:		Line 1:
	== Summary ==		== Summary ==
	~~Unaudited Results for the Year Ended 31 December 2021 & Investor Presentation~~

	Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces its unaudited results for the year ended 31 December 2021 (the "Period").		Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces its unaudited results for the year ended 31 December 2021 (the "Period").

95.149.241.133 at 20:50, 2 September 2022

2022-09-02T20:50:21Z

Show changes

95.149.241.133 at 20:44, 2 September 2022

2022-09-02T20:44:14Z

Show changes

95.149.241.133 at 20:34, 2 September 2022

2022-09-02T20:34:49Z

Show changes

95.149.241.133 at 20:31, 2 September 2022

2022-09-02T20:31:58Z

Show changes

95.149.241.133 at 20:15, 2 September 2022

2022-09-02T20:15:48Z

← Older revision		Revision as of 21:15, 2 September 2022
Line 689:		Line 689:

	Historically the Group's finance systems have recorded costs centrally and have managed costs in this way. Over recent years the Group has expanded both organically and through acquisition, increasing the number of products and services offered and in 2020 the Group reported through three operating segments, Study Management, Regulatory Solutions and In Silico Solutions. During 2021 the fourth segment, Clinical Trial Acceleration (CTA), was established after following the acquisition of d-wise.		Historically the Group's finance systems have recorded costs centrally and have managed costs in this way. Over recent years the Group has expanded both organically and through acquisition, increasing the number of products and services offered and in 2020 the Group reported through three operating segments, Study Management, Regulatory Solutions and In Silico Solutions. During 2021 the fourth segment, Clinical Trial Acceleration (CTA), was established after following the acquisition of d-wise.










	During 2020 this system enabled more centrally recorded costs to be allocated to the individual segments and that process was further developed during 2021. The operations of the Group are managed centrally with group-wide functions including sales, marketing, software development, information technology, customer support, human resources and finance & administration. The CTA segment already bears the majority of its costs directly and as such reports a lower direct contribution margin to central overheads than the other three segments. The expectation in future years is to be able to allocate more centrally held operational costs to the individual segments as internal reporting systems evolve, thereby assisting the Board to use the segmental cost information for meaningful decision making.		During 2020 this system enabled more centrally recorded costs to be allocated to the individual segments and that process was further developed during 2021. The operations of the Group are managed centrally with group-wide functions including sales, marketing, software development, information technology, customer support, human resources and finance & administration. The CTA segment already bears the majority of its costs directly and as such reports a lower direct contribution margin to central overheads than the other three segments. The expectation in future years is to be able to allocate more centrally held operational costs to the individual segments as internal reporting systems evolve, thereby assisting the Board to use the segmental cost information for meaningful decision making.




	The operations of the Group are managed centrally with group-wide functions including sales, marketing, software development, IT, customer support, human resources and finance & administration.		The operations of the Group are managed centrally with group-wide functions including sales, marketing, software development, IT, customer support, human resources and finance & administration.

			The analysis provided below reflects costs directly attributable to the respective segments in 2021 and 2020, which are primarily third party costs of sale and costs of allocated employees. The remaining indirect operational costs are accounted for centrally and are not allocated to specific segments.

			== Source(s) ==
			[https://www.investegate.co.uk/instem-plc--ins-/rns/final-results/202204260954033608J/ "Final Results]" — Instem plc, 26th April 2022.

			== Additional information ==
	~~The analysis provided below reflects costs directly attributable to~~ the respective segments in 2021 and 2020, which are primarily third party costs of sale and costs of allocated employees. The remaining indirect operational costs are accounted for centrally and are not allocated to specific segments.		Which is the main investment that this report is about? [[Main investment::Instem plc]]
			[[Category:Update]]
			[[Category:Instem plc]]
			__INDEX__

95.149.241.133: Created page with "== Summary == Unaudited Results for the Year Ended 31 December 2021 & Investor Presentation Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces its unaudited results for the year ended 31 December 2021 (the "Period"). '''Financial Highlights:''' * Revenues increased 63% to £46.0m (2020: £28.2m) ** Recurring revenue (annual support and SaaS) increased 43% to £24.1m (2020: £16.9m) with SaaS revenues increasing 21%..."

2022-09-02T20:14:24Z

Created page with "== Summary == Unaudited Results for the Year Ended 31 December 2021 & Investor Presentation Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces its unaudited results for the year ended 31 December 2021 (the "Period"). '''Financial Highlights:''' * Revenues increased 63% to £46.0m (2020: £28.2m) ** Recurring revenue (annual support and SaaS) increased 43% to £24.1m (2020: £16.9m) with SaaS revenues increasing 21%..."

Show changes